Sustained-release coating tablets are formulated in such a way that the release of the drug and its absorption will be slow. This will result in a lower peak blood level and hence, a lower risk of associated adverse effects such as gastrointestinal obstruction, nausea, vomiting and others. In sustained-release form, tablets can be administered in a single large dose just once a day. SR indicates sustained-release; a generic term that is used to describe the controlled release in the formulations of drugs that include alprazolam, bupropion, clomipramine, quetiapine, and others. Sustained-release coating tablets maintain uniform blood levels of the drug in the body and decrease the high blood levels, compared to immediate-release coating tablets.
Global Sustained Release Coating Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to drive the growth of the global sustained release coating market over the forecast period. The demand for coating tablets significantly rose during the pandemic. Pharmaceutical and biotech businesses and governments across the world have worked endlessly to combat the COVID-19 outbreak. As a result, it increased the production and demand for tablet coating. Because many affluent countries are witnessing a shortage of this medications, the booming demand has contributed to enormous prospects for developers of developers of drugs that are widely used to treat COVID-19 infection.
Increasing number of product approvals from regulatory bodies is expected to drive the growth of the global sustained release coating market over the forecast period. For instance, on August 13, 2021, Zydus Cadila, a pharmaceutical company, announced that it received final approval from the U.S. FDA to market Mesalamine Extended-Release Capsules in the strength of 0.375 g. Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
The global sustained release coating market is estimated to be valued at US$ 508.2 Mn in 2021 and is expected to exhibit a CAGR of 6.6% over the forecast period (2021-2028).
Figure 1: Global Sustained Release Coating Market Share (%) Analysis, By Polymer Material Type, 2021
Increasing number of product launches by the market players is expected to drive the growth of the global sustained release coating market over the forecast period.
Market players are focused on organic growth strategies such as product launches, which is expected to drive the growth of the market over the forecast period. For instance, in August 2020, Lupin Limited., a pharmaceutical company, announced the launch of Zileuton Extended-Release Tablets, 600 mg, for the treatment of chronic asthma in adults.
Increasing number of product approvals from regulatory bodies is expected to drive the growth of the global sustained release coating market over the forecast period.
Increasing approvals from the regulatory authorities is expected to drive the growth of the global sustained release coating market over the forecast period. For instance, on March 26, 2021, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved Myrbetriq (mirabegron extended-release tablets) for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq Granules (mirabegron for extended-release oral suspension), indicated for the treatment of NDO in pediatric patients aged 3 years and older.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: |
US$ 508.2 Mn |
| Historical Data for: | 2018 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 6.6% | 2028 Value Projection: |
US$ 794.9 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Evonik, BASF SE, Colorcon, Coating Place, Inc., Panchsheel Organics Ltd., Eastman Chemical Company, G.M. Chemie Pvt. Ltd., Ashland, Spraycel Coatings, JRS PHARMA, Merck KGaA, and Panacea Biotec |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Sustained Release Coating Market – Restraints
Increasing number of product recalls is expected to hinder the growth of the global sustained release coating market over the forecast period. For instance, on December 28, 2021, Viona Pharmaceuticals Inc., a pharmaceutical company, announced the recall of twenty three (23) lots of Metformin Hydrochloride Extended-Release Tablets, USP 750 mg. This product was manufactured by Cadila Healthcare Limited, a pharmaceutical company, Ahmedabad, India for the U.S. distribution by Viona Pharmaceuticals Inc.
Global Sustained Release Coating Market – Regional Analysis
On the basis of region, the global sustained release coating market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position during forecast period, owing to increasing number of inorganic growth strategies such as distribution agreement by market key players. For instance, in October 2018, Lannett Company, Inc., a manufacturer and distributor of generic products, announced that it entered into an agreement with Adare Pharmaceuticals, Inc., a pharmaceutical company, to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride Extended Release (ER) Capsules USP (CII), 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg.
Figure 2: Global Sustained Release Coating Market (US$ Mn), by Region, 2021
Global Sustained Release Coating Market – Competitive Landscape
Major players operating in the global sustained release coating market include Evonik, BASF SE, Colorcon, Coating Place, Inc., Panchsheel Organics Ltd., Eastman Chemical Company, G.M. Chemie Pvt. Ltd., Ashland, Spraycel Coatings, JRS PHARMA, Merck KGaA, and Panacea Biotec.
Sustained release coatings are designed to eliminate the need for multiple dosage regimens, particularly for those drugs whose action benefits from achieving reasonably constant blood levels over longer periods. Sustained release coatings are used for the drugs that need to be administered in high doses in the body. Sustained release coating products typically contain higher drug loadings than instant release (IR) products. Benefits of sustained release coating tablets include:
Market Dynamics
Increasing number of inorganic growth strategies by market key players is expected to drive the growth of global sustained release coating market during the forecast period. For instance, in May 2016, Colorcon, Inc., a provider of formulated film coating systems, and BASF, a chemical company, signed an agreement to strengthen their co-operation in the area of pharmaceutical film coatings. As a part of this agreement, BASF sold its Kollicoat IR Coating Systems product line, it is a powder, consists of 75% polyvinyl alcohol units and 25% polyethylene glycol units, to Colorcon, Inc.
Increasing number of product launches is expected to drive the growth of the global sustained release coating market. For instance, in October 2020, Evonik, a global leader for advanced drug delivery, announced the launch of a new ready-to-use powder premix blend of its EUDRAGIT functional polymers used for oral products with an immediate release profile.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients